SBIR/STTR Research Award
Biomaterials for mRNA based cellular reprogramming
Award amount
$290,999Program and phase
SBIR · Phase IAward year
2017Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- STEM PHARM, INCORPORATED
- Proposal award date
- 2017-02-01
- Contract end date
- 2018-07-31
- UEI
- YTLQLAJ53CB7
- Solicitation number
- PA14-307
- Topic code
- 100
Research abstract
Project Summary Abstract
Induced pluripotent stem cells iPSCs hold great promise in the areas of disease modeling and
regenerative medicine and as a result have unique commercial potential There are currently more than
ongoing clinical trials in stem cell therapies including the first in human trial using human iPSC
derived retinal pigment epithelial cells to treat macular degeneration Another set of recent studies have
shown direct reprogramming of target cells e g fibroblasts into neural or cardiac cell types via delivery
of genes encoding tissue specific transcription factors These scientific advances may lead to new
avenues for treatment of human diseases These potential therapeutic applications in addition to the
potential of reprogrammed human cells as unique research tools frame a substantial commercial
opportunity The initial and currently most commonly used methods of cellular reprogramming use
retroviral vectors to deliver reprogramming factors into the cells This method results in random
integration of reprogramming factors into the genome which is highly problematic for clinical use Non
integrative methods of delivering reprogramming factors include the use of episomal DNA or Sendai
Virus These methods work well for a variety of cell types however they require monitoring for vector
or viral clearance resulting in a longer workflow and increased labor and reagent costs There is a need
to develop commercial tools for safe efficient and adaptable cellular reprogramming with a particular
emphasis on non viral approaches for research and therapy A promising avenue for reprogramming
cells involves delivering mRNA that encodes reprogramming factors Using mRNA is especially attractive
as it dramatically reduces the risk of genomic integration and reduces the time required for clearance of
the reprogramming factors The goal of this proposed Phase I Project is to develop an mRNA delivery
system utilizing mineral coated microparticles and apply this innovative system for the generation of
foot print free iPSCs from clinically relevant cell types Specific aim will utilize our mineral coated
microparticles to deliver mRNA encoding fluorescent reporter proteins for the optimization of
transfection conditions to fibroblasts and blood derived cells Specific aim will use the optimized
conditions to deliver mRNA encoding reprogramming factors to fibroblasts and blood derived cells to
generate iPSCs which will be characterized for pluripotency expansion capability and karyotype stability
This work is significant as it will improve the work flow for mRNA reprogramming in fibroblasts and will
enable derivation of iPSCs from patient blood cells utilizing mRNA reprogramming This work is
innovative as it will improve mRNA delivery methods for these and other cell types which will lead to
further utilization of this technology in direct reprogramming differentiation and in vivo applications Public Health Relevance
Induced pluripotent stem cells have enormous promise for regenerative medicine and treating diseases
but researchers need better methods to generate those stem cells from patient samples We will
develop a new transfection technology to deliver mRNA to cells from patient samples to reprogram
those cells to the pluripotent state
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Development and Validation of a CNS Organoid Model of Temporal Lobe Epilepsy for Drug Discovery
- Human Neural Organoid Modeling of Alzheimer's Disease Neuroinflammation for Drug Discovery
- Neural organoid models of the immunological microenvironment of glioblastoma for drug discovery applications
- Hydrogel-enabled self-assembled human brain organoids for neurotoxicity applications
- Synthetic hydrogels for biomanufacturing of iPSC-derived neural cells for precision medicine
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- First-in-class TREM-1 inhibitors for neovascular retinal diseases
- Development of a Novel Biosensor to Accelerate Investigations of the Gut Microbiome
- Magnetic Lipid Nanoprobe Platform for Rapid, Highly-Efficient, and Cost-Effective Isolation of Extracellular Vesicles from Non-Invasive Bodily Fluids
- Scale-up and Manufacturing of STLR-201, an off-the-shelf regenerative therapeutic for Sjogren's syndrome-related dry eye disease
- Integrated assays of single-cell dynamics and molecular phenotype for cell therapy manufacturing